Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

CD62L as a therapeutic target in chronic lymphocytic leukemia.

Burgess M, Gill D, Singhania R, Cheung C, Chambers L, Renyolds BA, Smith L, Mollee P, Saunders N, McMillan NA.

Clin Cancer Res. 2013 Oct 15;19(20):5675-85. doi: 10.1158/1078-0432.CCR-13-1037. Epub 2013 Aug 15.

2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

Thioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro.

Bäckman E, Bergh AC, Lagerdahl I, Rydberg B, Sundström C, Tobin G, Rosenquist R, Linderholm M, Rosén A.

Haematologica. 2007 Nov;92(11):1495-504.

4.

Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease.

Vlad A, Deglesne PA, Letestu R, Saint-Georges S, Chevallier N, Baran-Marszak F, Varin-Blank N, Ajchenbaum-Cymbalista F, Ledoux D.

Cancer Res. 2009 Aug 15;69(16):6387-95. doi: 10.1158/0008-5472.CAN-08-4750. Epub 2009 Aug 4.

5.

Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.

Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M, Kreuzer KA.

Mol Med. 2011;17(7-8):619-27. doi: 10.2119/molmed.2010.00210. Epub 2011 Apr 14.

6.

Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells.

Brachtl G, Sahakyan K, Denk U, Girbl T, Alinger B, Hofbauer SW, Neureiter D, Hofbauer JP, Egle A, Greil R, Hartmann TN.

PLoS One. 2011;6(8):e23758. doi: 10.1371/journal.pone.0023758. Epub 2011 Aug 18.

7.
8.
9.

Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity.

Smit LA, Hallaert DY, Spijker R, de Goeij B, Jaspers A, Kater AP, van Oers MH, van Noesel CJ, Eldering E.

Blood. 2007 Feb 15;109(4):1660-8. Epub 2006 Oct 12.

10.

Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.

Maffei R, Fiorcari S, Bulgarelli J, Martinelli S, Castelli I, Deaglio S, Debbia G, Fontana M, Coluccio V, Bonacorsi G, Zucchini P, Narni F, Torelli G, Luppi M, Marasca R.

Haematologica. 2012 Jun;97(6):952-60. doi: 10.3324/haematol.2011.054924. Epub 2011 Dec 29.

11.

Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.

Morabito F, Mangiola M, Rapezzi D, Zupo S, Oliva BM, Ferraris AM, Spriano M, Rossi E, Stelitano C, Callea V, Cutrona G, Ferrarini M.

Haematologica. 2003 Aug;88(8):864-73.

12.

L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo.

Lafouresse F, Bellard E, Laurent C, Moussion C, Fournié JJ, Ysebaert L, Girard JP.

Blood. 2015 Sep 10;126(11):1336-45. doi: 10.1182/blood-2015-02-626291. Epub 2015 Jul 10.

13.

AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.

Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Mineur P, Le Roy C, Saint-Georges S, Varin-Blank N, Cymbalista F, Bron D, Lagneaux L.

Haematologica. 2012 Apr;97(4):608-15. doi: 10.3324/haematol.2011.052779. Epub 2011 Nov 4.

14.

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.

Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A.

Blood. 2012 Oct 25;120(17):3501-9. doi: 10.1182/blood-2012-02-414060. Epub 2012 Sep 5.

16.

Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.

Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, Ansell SM.

Mayo Clin Proc. 2004 Mar;79(3):318-25.

PMID:
15008605
17.

Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma.

Plander M, Ugocsai P, Seegers S, Orsó E, Reichle A, Schmitz G, Hofstädter F, Brockhoff G.

Ann Hematol. 2011 Dec;90(12):1381-90. doi: 10.1007/s00277-011-1218-z. Epub 2011 Apr 5.

PMID:
21465189
18.

Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.

Marquez ME, Hernández-Uzcátegui O, Cornejo A, Vargas P, Da Costa O.

Br J Haematol. 2015 Apr;169(2):211-8. doi: 10.1111/bjh.13286. Epub 2015 Jan 22.

PMID:
25612644
19.

Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro.

Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV.

Br J Haematol. 1996 Jan;92(1):97-103.

PMID:
8562418
20.

Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.

Huber S, Oelsner M, Decker T, zum Büschenfelde CM, Wagner M, Lutzny G, Kuhnt T, Schmidt B, Oostendorp RA, Peschel C, Ringshausen I.

Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.

PMID:
21293487

Supplemental Content

Support Center